Veru (NASDAQ:VERU – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01, Zacks reports. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.
Veru Price Performance
Shares of VERU stock traded up $0.06 during trading hours on Monday, reaching $0.79. The company had a trading volume of 2,370,238 shares, compared to its average volume of 1,602,859. The business has a fifty day simple moving average of $0.76 and a 200-day simple moving average of $0.82. Veru has a 12 month low of $0.36 and a 12 month high of $1.92. The company has a market cap of $114.97 million, a price-to-earnings ratio of -1.64 and a beta of -0.50.
Wall Street Analysts Forecast Growth
Separately, Oppenheimer reissued an “outperform” rating and issued a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th.
Veru Company Profile
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
- Five stocks we like better than Veru
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Insider Trading – What You Need to Know
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
